ProPhase Labs, Inc. Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount
ProPhase Labs, Inc. (PRPH) reported Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-06-01.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential · last filed 2026-06-01
- ProPhase Labs, Inc. effective income tax rate reconciliation, foreign income tax rate differential, amount for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- ProPhase Labs, Inc. effective income tax rate reconciliation, foreign income tax rate differential, amount for fiscal 2024 was $521.00K, a 2.16% increase from fiscal 2023.
- ProPhase Labs, Inc. effective income tax rate reconciliation, foreign income tax rate differential, amount for fiscal 2023 was $510.00K.
- ProPhase Labs, Inc. effective income tax rate reconciliation, foreign income tax rate differential, amount for fiscal 2022 was -$601.00K, a 364.76% decline from fiscal 2021.
| Period end | Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount 12 month | Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount 12 month as first filed |
|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-06-01 | |
| 2024-12-31 | $521.00K 10-K · filed 2026-06-01 | |
| 2023-12-31 | $510.00K 10-K · filed 2025-04-01 | |
| 2022-12-31 | -$601.00K 10-K · filed 2024-03-29 | |
| 2021-12-31 | $227.00K 10-K · filed 2023-03-29 | |
| 2020-12-31 | $159.00K 10-K · filed 2022-03-31 | |
| 2017-12-31 | $1.80M 10-K · filed 2019-03-26 | $1.64M 10-K · filed 2018-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |